Evidence map›Paper›PMID 37458923›Full record

ArticleNeurotoxicity research2023

Monoacylglycerol Lipase Inhibition Prevents Short-Term Mitochondrial Dysfunction and Oxidative Damage in Rat Brain Synaptosomal/Mitochondrial Fractions and Cortical Slices: Role of Cannabinoid Receptors.

Karen Jaqueline Paredes-Ruiz, Karla Chavira-Ramos, Sonia Galvan-Arzate, Edgar Rangel-López, Çimen Karasu, Isaac Túnez, Anatoly V Skalny, Tao Ke, Michael Aschner, Mario Orozco-Morales and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neurotoxicity research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 5 countries.

Karen Jaqueline Paredes-RuizLaboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, S.S.A, 14269, Mexico City, Mexico.
Karla Chavira-RamosLaboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, S.S.A, 14269, Mexico City, Mexico.
Sonia Galvan-ArzateDepartamento de Neuroquímica, Instituto Nacional de Neurología Y Neurocirugía, S.S.A, 14269, Mexico City, Mexico.
Edgar Rangel-LópezLaboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, S.S.A, 14269, Mexico City, Mexico.
Çimen KarasuCellular Stress Response and Signal Transduction Research Laboratory, Faculty of Medicine, Department of Medical Pharmacology, Gazi University, 06500, Beşevler, Ankara, Turkey.
Isaac TúnezInstituto de Investigaciones Biomédicas Maimonides de Córdoba (IMIBIC); Departamento de Bioquímica y Biología Molecular, Facultad de Medicina y Enfermería, Universidad de Córdoba Red Española de Excelencia en Estimulación Cerebral (REDESTIM), Córdoba, Spain.
Anatoly V SkalnyIM Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Tao KeDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, 11354, Bronx, NY, USA.
Michael AschnerDepartment of Molecular Pharmacology, Albert Einstein College of Medicine, 11354, Bronx, NY, USA.
Mario Orozco-MoralesLaboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía, S.S.A, 14269, Mexico City, Mexico.
Ana Laura Colín-GonzálezBanco de Tumores, Instituto Nacional de Cancerología, S.S.A., 14080, Mexico City, Mexico. coling.laura@gmail.com.
Abel SantamaríaLaboratorio de Aminoácidos Excitadores/Laboratorio de Neurofarmacología Molecular y Nanotecnología, Instituto Nacional de Neurología y Neurocirugía, S.S.A, 14269, Mexico City, Mexico. absada@yahoo.com.
Instituto Nacional de Neurología y Neurocirugía · MXAlbert Einstein College of Medicine · USGazi University · TRInstituto Maimónides de Investigación Biomédica de Córdoba · ESInstituto Nacional de Cancerología · MXPeoples' Friendship University of Russia · RU

Funding

EFFECTS OF DEHP ON LIVERR01ES003771 · NIEHS · WASHINGTON STATE UNIVERSITY · PI OKITA, RICHARD T. · 1986 to 1997
–
NIEHS NIH HHS R01ES03771
6 · The paper itself

Abstract

Inhibition of enzymes responsible for endocannabinoid hydrolysis represents an invaluable emerging tool for the potential treatment of neurodegenerative disorders. Monoacylglycerol lipase (MAGL) is the enzyme responsible for degrading 2-arachydonoylglycerol (2-AG), the most abundant endocannabinoid in the central nervous system (CNS). Here, we tested the effects of the selective MAGL inhibitor JZL184 on the 3-nitropropinic acid (3-NP)-induced short-term loss of mitochondrial reductive capacity/viability and oxidative damage in rat brain synaptosomal/mitochondrial fractions and cortical slices. In synaptosomes, while 3-NP decreased mitochondrial function and increased lipid peroxidation, JZL184 attenuated both markers. The protective effects evoked by JZL184 on the 3-NP-induced mitochondrial dysfunction were primarily mediated by activation of cannabinoid receptor 2 (CB2R), as evidenced by their inhibition by the selective CB2R inverse agonist JTE907. The cannabinoid receptor 1 (CB1R) also participated in this effect in a lesser extent, as evidenced by the CB1R antagonist/inverse agonist AM281. In contrast, activation of CB1R, but not CB2R, was responsible for the protective effects of JZL184 on the 3-NP-iduced lipid peroxidation. Protective effects of JZL184 were confirmed in other toxic models involving excitotoxicity and oxidative damage as internal controls. In cortical slices, JZL184 ameliorated the 3-NP-induced loss of mitochondrial function, the increase in lipid peroxidation, and the inhibition of succinate dehydrogenase (mitochondrial complex II) activity, and these effects were independent on CB1R and CB2R, as evidenced by the lack of effects of AM281 and JTE907, respectively. Our novel results provide experimental evidence that the differential protective effects exerted by JZL184 on the early toxic effects induced by 3-NP in brain synaptosomes and cortical slices involve MAGL inhibition, and possibly the subsequent accumulation of 2-AG. These effects involve pro-energetic and redox modulatory mechanisms that may be either dependent or independent of cannabinoid receptors' activation.

Indexed as

EndocannabinoidsSynaptosomesAnimalsBenzodioxolesBrainDrug Inverse AgonismMonoacylglycerol LipasesOxidative StressRatsReceptor, Cannabinoid, CB1Receptors, CannabinoidBenzodioxolesEndocannabinoidsMonoacylglycerol LipasesReceptor, Cannabinoid, CB1Receptors, CannabinoidEndocannabinoid systemJTE907JZL184Mitochondrial dysfunctionMonoacylglycerol lipase inhibitionOxidative damage

Identifiers

PMID37458923
OpenAlexW4384524602

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.